Company acquires exclusive rights to HIV antibody
BY Advocate.com Editors
May 15 2003 12:00 AM ET
Rockville, Md.-based Human Genome Sciences on Monday acquired exclusive rights to an antibody that could be used to slow HIV replication in the bodies of HIV-positive people, The Baltimore Sun reports. Under a licensing deal with Angenix, a California pharmaceutical company, HGS gained exclusive rights to the CCR5 mAb antibody, which prevents cellular HIV infection by jamming a key receptor on the surface of immune system cells that HIV must latch on to in order to enter the cells. A Phase I clinical trial of the antibody is planned to begin later this year.
- WATCH: This Indiana Pizzeria Won't Cater Gay Weddings
- More Celebs Tweet Off on Indiana
- WATCH: Seth Meyers Takes Down Indiana's New Antigay Legislation
- WATCH: Conan's Hilarious Interview With Indiana's 'Religious Freedom Czar'
- An Open Letter from a Transgender Rabbi to Trans Teens Everywhere
- Op-ed: 'Religious Discrimination' Laws Have Nothing to Do With Religion